Geron (GERN) Stock Research

Wednesday

Unusually active option classes on open August 5th

Aug 5, 9:40 AM

Geron sees FY26 revenue $220M-$240M, consensus $234.22M

GERN

Aug 5, 7:49 AM

Geron reports Q2 EPS (2c), consensus (1c)

GERN

Aug 5, 7:48 AM

Over a week ago

Geron appoints Chinmaya Rath as chief business officer

GERN

Jul 13, 8:05 AM

Geron to present RWE study of RYTELO at EHA Congress

GERN

May 12, 9:44 AM

Geron reports Q1 EPS (1c), consensus (2c)

GERN

May 6, 7:38 AM

Geron appoints Timothy Williams as chief legal officer

Apr 13, 8:21 AM

Geron files automatic mixed securities shelf

GERN

Mar 2, 7:50 AM

Geron sees FY26 Rytelo revenue $220M-$240M

GERN

Feb 25, 7:04 AM

Geron reports Q4 EPS (5c), consensus (4c)

GERN

Feb 25, 7:03 AM

Geron price target lowered by $1 at TD Cowen, here's why

GERN

Jan 29, 9:30 AM

Geron sees FY26 RYTELO product revenue $220M-$240M

GERN

Jan 12, 8:12 AM

What You Missed On Wall Street On Thursday

+25

Dec 11, 4:16 PM

Midday Fly By: Disney invests $1B in OpenAI, Oracle reports mixed Q2

+23

Dec 11, 12:04 PM

Geron announces restructuring plan, one-third workforce reduction

GERN

Dec 11, 8:03 AM

Geron announces new data presented at ASH 2025

GERN

Dec 8, 8:27 AM

Unusually active option classes on open November 14th

Nov 14, 9:40 AM

Geron sees FY25 operating expenses $250M-$260M

GERN

Nov 5, 7:32 AM

Geron reports Q3 EPS (3c), consensus (4c)

GERN

Nov 5, 7:31 AM

Geron COO Andrew Grethlein, CCO Jim Ziegler to depart

GERN

Oct 13, 4:39 PM

No more stories

First-to-Market Therapeutic Approval: Imetelstat (Rytelo) is the first and only telomerase inhibitor approved, offering a unique treatment option for a specific refractory lower-risk MDS patient population.

Differentiated Mechanism of Action: Its unique telomerase inhibition mechanism sets it apart from other MDS treatments, potentially offering distinct clinical benefits and a targeted patient population.

Strong Intellectual Property Portfolio: Robust patent protection for Imetelstat ensures market exclusivity and competitive insulation for a significant period.

Clinical Trial Outcomes Risk: IThe ongoing clinical trials for imetelstat may not yield sufficient efficacy or safety data, leading to delays or a halt in development.

Regulatory Approval Risk: IEven with positive clinical data, Geron may fail to obtain necessary regulatory approvals from health authorities like the FDA or EMA for imetelstat.

Commercialization Challenges Risk: IIf approved, Geron may face significant hurdles in commercializing imetelstat, including market access, pricing, reimbursement, and physician adoption challenges.

Charts